US pharma firms speed up work on coronavirus vaccine: Trump

Some of the American pharmaceutical companies have speed up their work towards finding a vaccine for the new coronavirus strain, President Donald Trump said on Monday, ahead of a meeting with executives of drug companies.

"I'm meeting with the pharmaceutical companies later on this afternoon. We have a big meeting with the biggest companies...we're talking about a vaccine... maybe a cure; it's possible. So, we'll see about that," Trump told reporters in the Oval Office of the White House.

"We're talking about a vaccine. They are moving along very quickly. All pharmaceutical companies are moving along very quickly," he said.

The US so far has reported 80 cases of infection and two deaths from COVID-19, which was first detected in China in December.

The US, Trump said, is working with other countries to find vaccine for the novel coronavirus.

"We're working very much with a lot of other countries on -- including Colombia -- but we're working with a lot of other countries on helping them with respect to this problem. And, again, we're doing very well," he said in the presence of his Columbian counterpart.


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel